lascufloxacin lascufloxacin lascufloxacin (trade name lasvic) is an fluoroquinolone antibiotic drug for the treatment of bacterial infections. it has been approved since 2019 in japan to treat community-acquired pneumonia, otorhinolaryngological infections, and respiratory tract infections. lascufloxacinclinical datatrade nameslasvicother nameskrp-am1977identifiers iupac name 7--4-fluoropyrrolidin-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxoquinoline-3-carboxylic acid cas number848416-07-9pubchem cid71528768iuphar/bps10823chemspider34985131unii55mob566v7keggd10772chemical and physical dataformulac21h24f3n3o4molar mass439.435 g·mol−13d model (jsmol)interactive image smiles coc1=c2c(=cc(=c1n3c((c3)f)cnc4cc4)f)c(=o)c(=cn2ccf)c(=o)o it has activity against various gram-positive bacteria including streptococcus pneumoniae and streptococcus anginosus.